- A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy2018 | Faculty of Medicine in Hradec Králové
- Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: successful treatment with risk-adapted rituximab-based immunochemotherapy2010 | Faculty of Medicine in Hradec Králové
- Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy2023 | First Faculty of Medicine, Second Faculty of Medicine
- Our experience with the immunochemotherapy in metastatic renal cancerPublication without faculty affiliation
- Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma2015 | First Faculty of Medicine
- Anti DR5 bound to HPMA: new approach for immunochemotherapy of cancerPublication without faculty affiliation
- Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial2016 | First Faculty of Medicine
- Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA2020 | First Faculty of Medicine
- Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study2016 | Publication without faculty affiliation
- Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial2018 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial2022 | First Faculty of Medicine
- Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy2019 | First Faculty of Medicine
- Urogenital lymphoma2015 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Efficacy and toxicity of combined immunochemotherapy in the treatment of patients with bronchogenic carcinoma with PD-L1 receptor expression < 1 % - case report2023 | First Faculty of Medicine
- The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group2018 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Third Faculty of Medicine, Second Faculty of Medicine
- Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.2010 | First Faculty of Medicine
- Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis2013 | Third Faculty of Medicine
- A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA2020 | First Faculty of Medicine
- Hepatic involvement in patients with non-Hodgkin's lymphoma2013 | First Faculty of Medicine
- Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network2014 | First Faculty of Medicine
- Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network2016 | Second Faculty of Medicine
- Non-Hodgkin lymphomas in the Czech Republic2019 | First Faculty of Medicine
- Comparison of contrast-enhanced CT-based response with PET assessment after first-line therapy for follicular lymphoma in the Phase III GALLIUM StudyPublication without faculty affiliation
- Molecular monitoring of residual disease in chronic lymphocytic leukemiaPublication without faculty affiliation
- Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study2019 | Faculty of Medicine in Hradec Králové
- Subcutaneous administration of rituximab in B-non-Hodgkin's lymphoma patients2014 | Publication without faculty affiliation
- Patient with follicular lymphoma and subcutaneous administration of rituximab2014 | Faculty of Medicine in Hradec Králové
- Modern, individualized treatment of chronic lymphotic leukemia2013 | First Faculty of Medicine
- Therapy of follicular lymphoma in 20192019 | Faculty of Medicine in Hradec Králové
- Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma2019 | First Faculty of Medicine